Gynecologic Oncology 32(1): 1-3, 1989.
Quinn MA, Campbell JJ
Forty-nine patients with advanced/recurrent endometrial carcinoma were treated with Tamoxifen, 20 mg, twice daily. There were six complete and four partial responses (response rate = 20%). The median survival of responders was 34 months compared to 6 months in nonresponders. Toxicity was minimal.
Rheinische Friedrich- Wilhelms- Universität Bonn